Report includes chapters which deeply display the following deliverable about industry :
• Pertuzumab Market Research Objective and Assumption
• Pertuzumab Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Pertuzumab Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Pertuzumab Market , By Regions
• Pertuzumab Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Pertuzumab Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Pertuzumab Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Pertuzumab Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Pertuzumab Market– Restraint
Increasing cost of anticancer drugs is expected to be a major factor hampering growth of the
market. For instance, in June 2017, The Scottish Medicines Consortium (SMC) denied access to
pertuzumab in England, which was available via the Cancer Drugs Fund (CDF) in Europe. The
drug was rejected by SMC as the treatment of HER2 positive breast cancer was not cost
effective when pertuzumab was used in combination with trastuzumab and docetaxel.
Moreover, according to a study published in the journal Oncology, September 2015, although
the use of pertuzumab with docetaxel and trastuzumab as first-line therapy for HER2 positive
breast cancer has been shown to yield a substantial survival benefit, the therapy is not cost
effective in the U.S. Also, according to the same source, the cost of treating HER2 positive
breast cancer with pertuzumab and other drugs is US$ 509,845 and that with only docetaxel
and trastuzumab is US$ 135,092.